1. Home
  2. GECC vs ONCY Comparison

GECC vs ONCY Comparison

Compare GECC & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Great Elm Capital Corp.

GECC

Great Elm Capital Corp.

N/A

Current Price

$4.90

Market Cap

68.3M

Sector

Finance

ML Signal

N/A

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

N/A

Current Price

$0.42

Market Cap

80.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GECC
ONCY
Founded
2016
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.3M
80.5M
IPO Year
2016
2002

Fundamental Metrics

Financial Performance
Metric
GECC
ONCY
Price
$4.90
$0.42
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $4.43
AVG Volume (30 Days)
91.1K
★ 994.1K
Earning Date
11-02-2026
11-13-2026
Dividend Yield
★ 20.24%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.10
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.98
N/A
P/E Ratio
$49.30
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$0.33
52 Week High
$7.97
$1.30

Technical Indicators

Market Signals
Indicator
GECC
ONCY
Relative Strength Index (RSI) 44.69 41.91
Support Level $4.73 N/A
Resistance Level $5.17 $0.46
Average True Range (ATR) 0.18 0.05
MACD 0.01 0.01
Stochastic Oscillator 47.57 56.03

Price Performance

Historical Comparison
GECC
ONCY

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Share on Social Networks: